CN109939135A - A kind of ketogenic parenteral nutrition solution and preparation method thereof - Google Patents
A kind of ketogenic parenteral nutrition solution and preparation method thereof Download PDFInfo
- Publication number
- CN109939135A CN109939135A CN201910213658.3A CN201910213658A CN109939135A CN 109939135 A CN109939135 A CN 109939135A CN 201910213658 A CN201910213658 A CN 201910213658A CN 109939135 A CN109939135 A CN 109939135A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- ketogenic
- solution
- glucose
- parenteral nutrition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 230000002361 ketogenic effect Effects 0.000 title claims description 59
- 239000003182 parenteral nutrition solution Substances 0.000 title claims description 34
- 150000001413 amino acids Chemical class 0.000 claims abstract description 78
- 229940088594 vitamin Drugs 0.000 claims abstract description 71
- 229930003231 vitamin Natural products 0.000 claims abstract description 71
- 235000013343 vitamin Nutrition 0.000 claims abstract description 71
- 239000011782 vitamin Substances 0.000 claims abstract description 71
- 239000000243 solution Substances 0.000 claims abstract description 67
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 62
- 239000008103 glucose Substances 0.000 claims abstract description 62
- 239000000126 substance Substances 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000008215 water for injection Substances 0.000 claims abstract description 33
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 25
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 25
- 239000011707 mineral Substances 0.000 claims abstract description 25
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 17
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 14
- 239000001632 sodium acetate Substances 0.000 claims abstract description 14
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 14
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract 3
- 229940024606 amino acid Drugs 0.000 claims description 79
- 235000001014 amino acid Nutrition 0.000 claims description 77
- 239000011259 mixed solution Substances 0.000 claims description 62
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 239000002960 lipid emulsion Substances 0.000 claims description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 8
- 239000004473 Threonine Substances 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- 235000004279 alanine Nutrition 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 235000009697 arginine Nutrition 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- 229960000310 isoleucine Drugs 0.000 claims description 8
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 8
- 229930182817 methionine Natural products 0.000 claims description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
- 235000013930 proline Nutrition 0.000 claims description 8
- 235000004400 serine Nutrition 0.000 claims description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
- 235000002374 tyrosine Nutrition 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 229940055726 pantothenic acid Drugs 0.000 claims description 6
- 235000019161 pantothenic acid Nutrition 0.000 claims description 6
- 239000011713 pantothenic acid Substances 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
- 235000021323 fish oil Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 235000008390 olive oil Nutrition 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- 239000011772 phylloquinone Substances 0.000 claims description 4
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical group CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 3
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 3
- 229960003080 taurine Drugs 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- -1 tyrosine Amino acid Chemical class 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 239000008344 egg yolk phospholipid Substances 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 abstract description 15
- 150000002576 ketones Chemical class 0.000 abstract description 11
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 abstract description 8
- 230000007812 deficiency Effects 0.000 abstract description 4
- 206010015037 epilepsy Diseases 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 208000030159 metabolic disease Diseases 0.000 abstract description 3
- 208000027219 Deficiency disease Diseases 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 abstract 1
- 108091052347 Glucose transporter family Proteins 0.000 abstract 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 16
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 235000013350 formula milk Nutrition 0.000 description 14
- 238000001802 infusion Methods 0.000 description 14
- 230000009286 beneficial effect Effects 0.000 description 11
- 235000020887 ketogenic diet Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 5
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 229960002885 histidine Drugs 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 229960002898 threonine Drugs 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 206010008635 Cholestasis Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 230000007870 cholestasis Effects 0.000 description 3
- 231100000359 cholestasis Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 208000003243 intestinal obstruction Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000004213 low-fat Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 3
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010021750 Infantile Spasms Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 201000006791 West syndrome Diseases 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000029751 Amino acid metabolism disease Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 description 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 description 1
- 208000005018 Hyperlactatemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000020616 amino acid formula Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
技术领域technical field
本发明涉及医用肠外营养制剂,具体涉及一种生酮肠外营养液及其制备方法。The invention relates to a medical parenteral nutrition preparation, in particular to a ketogenic parenteral nutrition solution and a preparation method thereof.
背景技术Background technique
生酮饮食是一种高脂肪低碳水化合物的饮食,最初于1921年由Mayo Clinic的Wilder博士提出并应用于治疗难治性癫痫,取得较好的疗效(陈文杰,秦炯.生酮饮食疗法治疗儿童难治性癫痫作用机制研究进展[J].中华实用儿科临床杂志,2017,32(24):1912-1914.)。此后,在其他遗传代谢性疾病如葡萄糖载体缺乏症、丙酮酸脱氢酶缺乏症、部分肿瘤(Vidali S,Aminzadeh S,Lambert B,et al.Mitochondria:the ketogenic diet-ametabolism-based therapy.Int J Biochem Cell Biol.2015;63:55-59.)等中运用,均取得不错的效果。然而,不管是上述那种患者,一旦发生胃肠道梗阻、肠瘘、活动性出血等疾病则不得不禁食(焦广宇,李增宁,陈伟.临床营养学[M].北京:人民卫生出版社,2017:106.),生酮饮食无法延续。这种情况常常给临床医生造成治疗困难:如果通过普通的葡萄糖或氨基酸进补液,会导致患者酮体迅速降低,可能诱发原本控制好的癫痫等再次发作。如果单纯使用脂肪乳剂,又可能导致恶心、呕吐、胆汁淤积等肠外营养并发症。因此,研发科学的、安全有效的、配比合理的生酮肠外营养配方,对于生酮患者有特殊的意义。The ketogenic diet is a high-fat and low-carbohydrate diet, which was first proposed by Dr. Wilder of Mayo Clinic in 1921 and applied to the treatment of refractory epilepsy, and achieved good results (Chen Wenjie, Qin Jiong. Ketogenic diet therapy for children Research progress on the mechanism of refractory epilepsy[J]. Chinese Journal of Practical Pediatrics, 2017, 32(24): 1912-1914.). Since then, in other genetic metabolic diseases such as glucose carrier deficiency, pyruvate dehydrogenase deficiency, some tumors (Vidali S, Aminzadeh S, Lambert B, et al. Mitochondria: the ketogenic diet-ametabolism-based therapy. Int J Biochem Cell Biol. 2015; 63: 55-59.), etc., all achieved good results. However, no matter the above-mentioned patients, once they have gastrointestinal obstruction, intestinal fistula, active bleeding and other diseases, they have to fast (Jiao Guangyu, Li Zengning, Chen Wei. Clinical Nutrition [M]. Beijing: People's Health Publishing House) , 2017:106.), the ketogenic diet cannot continue. This situation often makes treatment difficult for clinicians: if normal glucose or amino acids are used for rehydration, the patient's ketone bodies will rapidly decrease, which may induce seizures such as epilepsy that were originally controlled. If the fat emulsion is used alone, it may lead to complications of parenteral nutrition such as nausea, vomiting, and cholestasis. Therefore, the development of scientific, safe and effective ketogenic parenteral nutrition formulas with reasonable proportions is of special significance for ketogenic patients.
中国专利数据库中涉及生酮配方的申请全部为经胃肠道补充的制剂。迄今为止,并无专用于肠道外营养(经过静脉输注)的生酮配方专利。All applications involving ketogenic formulations in the Chinese patent database are formulations supplemented by the gastrointestinal tract. To date, there are no patents on ketogenic formulations dedicated to parenteral nutrition (via intravenous infusion).
发明内容SUMMARY OF THE INVENTION
本发明所要解决的技术问题是提供一种生酮肠外营养液及其制备方法,所提供的高脂低糖低氨基酸营养液配方,在患者不得不禁食的情况下,通过输入该营养液很好的治疗难治性癫痫以及其他遗传代谢性疾病如葡萄糖载体缺乏症、丙酮酸脱氢酶缺乏症、部分肿瘤等,填补了生酮肠外营养液技术的空白。The technical problem to be solved by the present invention is to provide a ketogenic parenteral nutrient solution and a preparation method thereof. The high-fat, low-sugar, and low-amino acid nutrient solution formula provided by the present invention can be easily absorbed by the patient when the patient has to fast. Good treatment of refractory epilepsy and other genetic metabolic diseases such as glucose carrier deficiency, pyruvate dehydrogenase deficiency, some tumors, etc., fill the gap of ketogenic parenteral nutrition technology.
本发明解决上述技术问题的技术方案如下:一种生酮肠外营养液,包括溶解在注射用水中的以下物质:氨基酸、脂肪类物质、葡萄糖、维生素、矿物质、乳化剂和醋酸钠;各组分的质量分数为:氨基酸1.80~3.3g/100mL,脂肪类物质6.5~8.0g/100mL,葡萄糖0.2~0.7g/100mL,维生素28.93mg/100mL,矿物质327.33mg/100ml,乳化剂1.32~1.49g/100mL,醋酸钠2.34~4.29mmol/100mL。The technical solution of the present invention to solve the above-mentioned technical problems is as follows: a ketogenic parenteral nutrition solution, comprising the following substances dissolved in water for injection: amino acids, fatty substances, glucose, vitamins, minerals, emulsifiers and sodium acetate; The mass fraction of components is: amino acid 1.80~3.3g/100mL, fatty substance 6.5~8.0g/100mL, glucose 0.2~0.7g/100mL, vitamin 28.93mg/100mL, mineral 327.33mg/100ml, emulsifier 1.32~ 1.49g/100mL, sodium acetate 2.34~4.29mmol/100mL.
本发明的有益效果是:本发明主要用于已采用生酮饮食控制疾病的患者(如控制癫痫发作)在其发生较重的胃肠功能障碍(如肠梗阻、活动性出血等)而禁食时,不能使用普通高糖低脂等普通肠外营养配方状态,本发明可以有效维持禁食患儿的血酮水平,避免疾病发作,同时保证总能量摄入,是生酮患儿禁食期间的理想营养保障,同时,与普通肠外营养液高糖低脂适量氨基酸配方不同,本发明为高脂低糖低氨基酸配方,根据生酮患儿(难治性癫痫或其他相关代谢疾病)的对供能营养素的特殊需求,提高了肠外营养配方中脂肪乳剂的比例,降低了氨基酸和葡萄糖的比例,确定维生素和矿物质的需求,在患儿中使用安全有效,输注后可以维患者血酮在理想范围、血糖也在正常范围,不诱发患者癫痫发作(或诱发糖代谢异常患者的高乳酸血症),有效解决服用生酮饮食的患者在禁食期间的营养需求;该配方的脂肪类物质可以防止高血脂、肝损害、胆汁淤积,尽可能减少高脂配方的不良反应;配方中强化了维生素B2、烟酸、泛酸的剂量,可以加快有脂肪β氧化,进一步减脂肪超载的可能;该肠外营养配方渗透压均小于600mOsm/L,在外周静脉可以耐受的范围内(900mOsm/L),患者输注疼痛感小,且不容易引起脉管炎;所述葡萄糖为医用葡萄糖溶液中的葡萄糖,少量的葡萄糖溶液可以平衡脂肪代谢,不影响生酮,同时降低低血糖发生的几率;乳化剂使得脂肪类物质成为可吸收的形式;矿物质的作用是维持人体正常生理功能;氨基酸的作用保证儿童对必需氨基酸的需求,避免负氮平衡;醋酸钠是无水醋酸在最终溶液中的存在模式,无水醋酸是为了使生酮营养液的PH能够稳定在人体能够接受的范围内,保证输注安全性。The beneficial effects of the present invention are as follows: the present invention is mainly used for patients who have adopted ketogenic diet to control diseases (such as controlling epilepsy) and fasting when they have severe gastrointestinal dysfunction (such as intestinal obstruction, active bleeding, etc.). At the same time, the state of common parenteral nutrition formulas such as common high sugar and low fat cannot be used, and the present invention can effectively maintain the blood ketone level of fasting children, avoid disease outbreaks, and at the same time ensure total energy intake, which is the best time for ketogenic children during fasting. At the same time, the present invention is a high-fat, low-sugar and low-amino acid formula, which is different from ordinary parenteral nutrition solution high-sugar, low-fat and appropriate amino acid formula. The special needs of energy-supplying nutrients increase the proportion of fat emulsions in parenteral nutrition formula, reduce the proportion of amino acids and glucose, determine the needs of vitamins and minerals, are safe and effective in children, and can maintain the blood of patients after infusion. Ketones are in the ideal range and blood sugar is also in the normal range, do not induce seizures in patients (or induce hyperlactatemia in patients with abnormal glucose metabolism), and effectively meet the nutritional needs of patients taking the ketogenic diet during fasting; the fat of the formula These substances can prevent hyperlipidemia, liver damage, cholestasis, and minimize the adverse reactions of high-fat formulas; the formula has enhanced doses of vitamin B2, niacin, and pantothenic acid, which can accelerate fat beta oxidation and further reduce fat overload. Possibly; the osmotic pressure of the parenteral nutrition formula is less than 600mOsm/L, which is within the range that the peripheral vein can tolerate (900mOsm/L), the patient feels less pain during infusion, and it is not easy to cause vasculitis; the glucose is medical Glucose in glucose solution, a small amount of glucose solution can balance fat metabolism without affecting ketone production, and at the same time reduce the probability of hypoglycemia; emulsifier makes fatty substances into an absorbable form; the role of minerals is to maintain normal physiological functions of the human body ; The role of amino acids guarantees children's demand for essential amino acids and avoids negative nitrogen balance; Sodium acetate is the mode of existence of anhydrous acetic acid in the final solution, and anhydrous acetic acid is to stabilize the pH of the ketogenic nutrient solution at an acceptable level for the human body within the range to ensure the safety of infusion.
在上述技术方案的基础上,本发明还可以做如下改进:On the basis of above-mentioned technical scheme, the present invention can also do following improvement:
进一步,所述脂肪重量与所述葡萄糖和所述氨基酸重量之和的比例为2:1~4:1,所述氨基酸为18种或者19种。Further, the ratio of the weight of the fat to the sum of the weight of the glucose and the amino acid is 2:1 to 4:1, and the number of the amino acids is 18 or 19.
采用上述进一步方案的有益效果是氨基酸为19种氨基酸适用于3岁以下儿童,氨基酸为18种适用于3岁及以上人群,能够满足不同年龄段患者对氨基酸的不同需求。The beneficial effect of the above-mentioned further scheme is that 19 kinds of amino acids are suitable for children under 3 years old, and 18 kinds of amino acids are suitable for people over 3 years old, which can meet the different needs of patients of different ages for amino acids.
进一步,所述18种氨基酸为异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、苏氨酸、色氨酸、缬氨酸、胱氨酸、组氨酸、酪氨酸、丙氨酸、精氨酸、脯氨酸、丝氨酸、门冬氨酸、谷氨酸和甘氨酸;各种氨基酸的质量比为异亮氨酸:亮氨酸:赖氨酸:甲硫氨酸:苯丙氨酸:苏氨酸:色氨酸:缬氨酸:胱氨酸:组氨酸:酪氨酸:丙氨酸:精氨酸:脯氨酸:丝氨酸:门冬氨酸:谷氨酸:甘氨酸=33:56:23:13:19:17:8:31:1:19:9:21:49:27:15:13:20:15。Further, the 18 amino acids are isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, cystine, histidine , tyrosine, alanine, arginine, proline, serine, aspartic acid, glutamic acid and glycine; the mass ratio of various amino acids is isoleucine:leucine:lysine: Methionine: Phenylalanine: Threonine: Tryptophan: Valine: Cystine: Histidine: Tyrosine: Alanine: Arginine: Proline: Serine: Aspart Amino acid: glutamic acid: glycine = 33:56:23:13:19:17:8:31:1:19:9:21:49:27:15:13:20:15.
采用上述进一步方案的有益效果是平衡基酸模式,提高氨基酸利用率。The beneficial effect of adopting the above-mentioned further scheme is to balance the amino acid pattern and improve the utilization rate of amino acids.
进一步,所述19种氨基酸为异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、苏氨酸、色氨酸、缬氨酸、半胱氨酸、组氨酸、酪氨酸、丙氨酸、精氨酸、脯氨酸、丝氨酸、门冬氨酸、谷氨酸、甘氨酸和牛磺酸;各种氨基酸的质量比为异亮氨酸:亮氨酸:赖氨酸:甲硫氨酸:苯丙氨酸:苏氨酸:色氨酸:缬氨酸:半胱氨酸:组氨酸:酪氨酸:丙氨酸:精氨酸:脯氨酸:丝氨酸:门冬氨酸:谷氨酸:甘氨酸:牛磺酸=33:56:23:13:19:17:8:31:1:19:9:21:49:27:15:13:20:15:1。Further, the 19 amino acids are isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, cysteine, histidine acid, tyrosine, alanine, arginine, proline, serine, aspartic acid, glutamic acid, glycine and taurine; the mass ratio of various amino acids is isoleucine:leucine: Lysine: Methionine: Phenylalanine: Threonine: Tryptophan: Valine: Cysteine: Histidine: Tyrosine: Alanine: Arginine: Proline :serine:aspartic acid:glutamic acid:glycine:taurine=33:56:23:13:19:17:8:31:1:19:9:21:49:27:15:13: 20:15:1.
采用上述进一步方案的有益效果是平衡氨基酸模式,提高氨基酸利用率,同时满足3岁以下儿童的氨基酸需求。The beneficial effect of adopting the above-mentioned further scheme is to balance the amino acid pattern, improve the utilization rate of amino acids, and meet the amino acid requirements of children under 3 years old at the same time.
进一步,所述脂肪类物质为中链甘油三酯、橄榄油、大豆油和鱼油,所述脂肪类物质各组分的质量比为中链甘油三酯:橄榄油:大豆油:鱼油=7:4:7:2;所述乳化剂为蛋黄卵磷脂、甘油、油酸钠,所述乳化剂各组分的质量比为蛋黄卵磷脂:甘油:油酸钠=43:89:1。Further, the fatty substance is medium chain triglyceride, olive oil, soybean oil and fish oil, and the mass ratio of each component of the fatty substance is medium chain triglyceride: olive oil: soybean oil: fish oil=7: 4:7:2; the emulsifier is egg yolk lecithin, glycerol, and sodium oleate, and the mass ratio of each component of the emulsifier is egg yolk lecithin:glycerol:sodium oleate=43:89:1.
采用上述进一步方案的有益效果是中链脂肪可以快速入肝氧化生成酮体供能,橄榄油可以提供单不饱和脂肪酸,大豆油可以满足必需脂肪酸需求,鱼油可以调节免疫反应并控制炎症反应,多种油合理的比例混合,可以大大降低本高脂肪肠外营养配方造成高血脂、肝损害、胆汁淤积的风险;三种乳化剂的加入使得油类物质能够有效乳化成能够被人体吸收的形式。The beneficial effect of adopting the above-mentioned further scheme is that medium-chain fat can be rapidly oxidized into the liver to generate ketone bodies for energy supply, olive oil can provide monounsaturated fatty acids, soybean oil can meet the needs of essential fatty acids, fish oil can regulate immune response and control inflammatory response, and more Mixing these oils in a reasonable proportion can greatly reduce the risk of hyperlipidemia, liver damage and cholestasis caused by this high-fat parenteral nutrition formula; the addition of three emulsifiers enables the oil substances to be effectively emulsified into a form that can be absorbed by the human body.
进一步,所述维生素为脂溶性维生素和水溶性维生素的混合物,所述脂溶性维生素为维生素A、维生素D2、维生素E和维生素K1,所述水溶性维生素为维生素B1、维生素B2、烟酸、维生素B6、泛酸、维生素C、生物素、叶酸和维生素B12,各种维生素的质量比为维生素A:维生素D2:维生素E:维生素K1:维生素B1:维生素B2:烟酸:维生素B6:泛酸:维生素C:生物素:叶酸:维生素B12=700:10:7000:300:3800:9000:100000:5000:38000:125000:75:500:6.3。Further, the vitamins are a mixture of fat-soluble vitamins and water-soluble vitamins, the fat-soluble vitamins are vitamin A, vitamin D 2 , vitamin E and vitamin K 1 , and the water-soluble vitamins are vitamin B 1 , vitamin B 2 , Niacin, vitamin B 6 , pantothenic acid, vitamin C, biotin, folic acid and vitamin B 12 , the mass ratio of various vitamins is vitamin A: vitamin D 2 : vitamin E: vitamin K 1 : vitamin B 1 : vitamin B 2 : Niacin: vitamin B6: pantothenic acid: vitamin C: biotin: folic acid: vitamin B12 = 700: 10 :7000: 300 :3800:9000:100000:5000:38000:125000:75:500:6.3.
采用上述进一步方案的有益效果是其中特别强化了维生素B2、烟酸、泛酸的剂量,有利于加快脂肪β氧化,避免高脂配方相关的不良反应。The beneficial effect of adopting the above-mentioned further scheme is that the doses of vitamin B2, niacin, and pantothenic acid are specially strengthened, which is beneficial to accelerate the β-oxidation of fat and avoid the adverse reactions related to the high-fat formula.
进一步,所述矿物质为钠、钾、氯、锌、铜、锰、硒、氟和碘,所述矿物质各组分的质量比为钠:钾:氯:锌:铜:锰:硒:氟:碘=52000:88000:187000:250:20:1:2:57:1。Further, the minerals are sodium, potassium, chlorine, zinc, copper, manganese, selenium, fluorine and iodine, and the mass ratio of each component of the minerals is sodium: potassium: chlorine: zinc: copper: manganese: selenium: Fluorine:Iodine=52000:88000:187000:250:20:1:2:57:1.
采用上述进一步方案的有益效果是保证儿童对不同矿物质的不同日常需求,维持正常生理功能。The beneficial effect of adopting the above-mentioned further scheme is to ensure that children have different daily requirements for different minerals and maintain normal physiological functions.
一种生酮肠外营养液的制备方法,包括如下步骤:A preparation method of a ketogenic parenteral nutrition solution, comprising the following steps:
步骤1:称取对应量的氨基酸和对用量的无水醋酸与注射用水配制成氨基酸溶液,称取对应量的葡萄糖与注射用水配制成葡萄糖溶液,称取对应量的脂肪类物质,对应量的乳化剂和对应量的氢氧化钠与注射用水配制成脂肪乳剂;Step 1: Weigh the corresponding amount of amino acid and the corresponding amount of anhydrous acetic acid and water for injection to prepare an amino acid solution, weigh the corresponding amount of glucose and water for injection to prepare a glucose solution, weigh the corresponding amount of fatty substances, and weigh the corresponding amount of fatty substances. Emulsifier and corresponding amount of sodium hydroxide and water for injection are formulated into fat emulsion;
步骤2:称取对应量的矿物质,加入步骤1中的氨基酸溶液,得到第一混合液;Step 2: Weigh the corresponding amount of minerals, add the amino acid solution in Step 1 to obtain the first mixed solution;
步骤3:称取对应量的维生素,将所述维生素中脂溶性的维生素加入步Step 3: Weigh the corresponding amount of vitamins, and add the fat-soluble vitamins in the vitamins to step 3.
骤1中的脂肪乳剂,得到第二混合液;将所述维生素中水溶性的维生素The fat emulsion in step 1 obtains the second mixed solution; the water-soluble vitamins in the vitamins are
加入步骤1中的葡萄糖溶液,得到第三混合液;Add the glucose solution in step 1 to obtain the third mixed solution;
步骤4:将步骤2中的第一混合液与步骤3中的第二混合液和第三混合液混合,得到所述生酮肠外营养液。Step 4: Mix the first mixed solution in step 2 with the second mixed solution and the third mixed solution in step 3 to obtain the ketogenic parenteral nutrition solution.
采用上述进一步方案的有益效果是通过合理的步骤,使得各成分能够充分发挥作用。The beneficial effect of adopting the above-mentioned further scheme is that through reasonable steps, each component can fully function.
进一步,所述氨基酸溶液中氨基酸的质量浓度为6%或10%,所述葡萄糖溶液的质量浓度为10%,所述脂肪乳剂中油类物质的质量浓度为20%。Further, the mass concentration of amino acids in the amino acid solution is 6% or 10%, the mass concentration of the glucose solution is 10%, and the mass concentration of oil substances in the fat emulsion is 20%.
采用上述进一步方案的有益效果是选用合适的浓度结合用量得到所需浓度的生酮肠外营养液。The beneficial effect of adopting the above-mentioned further scheme is to select the appropriate concentration and dosage to obtain the ketogenic parenteral nutrition solution of the desired concentration.
进一步,还包括补充水分的步骤,在所述步骤4中将第一混合液、第二混合液和第三混合液混合后,补充水分至一定浓度。Further, it also includes a step of replenishing water. In the step 4, after mixing the first mixed solution, the second mixed solution and the third mixed solution, add water to a certain concentration.
采用上述进一步方案的有益效果是将第一混合液、第二混合液和第三混合液混合后补充水分得到所需浓度的生酮肠外营养液。The beneficial effect of adopting the above-mentioned further solution is that the first mixed solution, the second mixed solution and the third mixed solution are mixed and then supplemented with water to obtain a ketogenic parenteral nutrition solution with a desired concentration.
具体实施方式Detailed ways
以下对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。The principles and features of the present invention are described below, and the examples are only used to explain the present invention, but not to limit the scope of the present invention.
实施例1Example 1
本实施例为4:1型生酮(脂肪类物质重量:葡萄糖和氨基酸重量之和为4:1),适用于3岁以下儿童。肠外生酮营养液的参数为能量:80.3kcal/100ml,渗透压:421mOsm/L,氨基酸1.8g/100mL,脂肪类物质8.0g/100mL,葡萄糖0.2g/100mL,维生素28.93mg/100mL,矿物质327.33mg/ml,乳化剂1.49g/100mL,醋酸钠2.34mmol/100mL。This example is 4:1 ketogenic (the weight of fatty substances: the sum of the weight of glucose and amino acids is 4:1), which is suitable for children under 3 years old. The parameters of parenteral ketogenic nutrient solution are energy: 80.3kcal/100ml, osmotic pressure: 421mOsm/L, amino acid 1.8g/100mL, fatty substance 8.0g/100mL, glucose 0.2g/100mL, vitamin 28.93mg/100mL, mineral Substance 327.33mg/ml, emulsifier 1.49g/100mL, sodium acetate 2.34mmol/100mL.
生酮肠外营养液的制备方法:Preparation method of ketogenic parenteral nutrition solution:
步骤1:称取对应量的氨基酸和无水醋酸与注射用水配制成氨基酸溶液,称取对应量的葡萄糖与注射用水配制成葡萄糖溶液,称取对应量的脂肪类物质、乳化剂和氢氧化钠与注射用水配制成脂肪乳剂;Step 1: Weigh corresponding amounts of amino acids and anhydrous acetic acid and water for injection to prepare amino acid solution, take corresponding amounts of glucose and water for injection to prepare glucose solution, weigh corresponding amounts of fatty substances, emulsifier and sodium hydroxide It is formulated into a fat emulsion with water for injection;
步骤2:称取对应量的矿物质,加入步骤1中的氨基酸溶液,得到第一混合液;Step 2: Weigh the corresponding amount of minerals, add the amino acid solution in Step 1 to obtain the first mixed solution;
步骤3:称取对应量的维生素,将所述维生素中脂溶性的维生素加入步骤1中的脂肪乳剂,得到第二混合液;将所述维生素中水溶性的维生素加入步骤1中的葡萄糖溶液,得到第三混合液;Step 3: Weigh the corresponding amount of vitamins, add the fat-soluble vitamins in the vitamins to the fat emulsion in step 1 to obtain a second mixed solution; add the water-soluble vitamins in the vitamins to the glucose solution in step 1, to obtain the third mixed solution;
步骤4:将步骤2中的第一混合液与步骤3中的第二混合液和第三混合液混合,补充注射用水,得到生酮肠外营养液。Step 4: Mix the first mixed solution in step 2 with the second mixed solution and the third mixed solution in step 3, and supplement water for injection to obtain a ketogenic parenteral nutrition solution.
实施例2Example 2
本实施例为3:1型生酮(脂肪类物质重量:葡萄糖和氨基酸重量之和为3:1),适用于3岁以下儿童。肠外生酮营养液的参数为能量:73.6kcal/100ml,渗透压:428mOsm/L,氨基酸1.98g/100mL,脂肪类物质7.1g/100mL,葡萄糖0.35g/100mL,维生素28.93mg/100mL,矿物质327.33mg/ml,乳化剂1.32g/100mL,醋酸钠2.57mmol/100mL。This example is 3:1 ketogenic (the weight of fatty substances: the sum of the weight of glucose and amino acids is 3:1), which is suitable for children under 3 years old. The parameters of parenteral ketogenic nutrient solution are energy: 73.6kcal/100ml, osmotic pressure: 428mOsm/L, amino acid 1.98g/100mL, fatty substance 7.1g/100mL, glucose 0.35g/100mL, vitamin 28.93mg/100mL, mineral Substance 327.33mg/ml, emulsifier 1.32g/100mL, sodium acetate 2.57mmol/100mL.
生酮肠外营养液的制备方法:The preparation method of ketogenic parenteral nutrition solution:
步骤1:称取对应量的氨基酸和无水醋酸与注射用水配制成氨基酸溶液,称取对应量的葡萄糖与注射用水配制成葡萄糖溶液,称取对应量的脂肪类物质、乳化剂和氢氧化钠与注射用水配制成脂肪乳剂;Step 1: Weigh corresponding amounts of amino acids and anhydrous acetic acid and water for injection to prepare amino acid solution, take corresponding amounts of glucose and water for injection to prepare glucose solution, weigh corresponding amounts of fatty substances, emulsifier and sodium hydroxide It is formulated into a fat emulsion with water for injection;
步骤2:称取对应量的矿物质,加入步骤1中的氨基酸溶液,得到第一混合液;Step 2: Weigh the corresponding amount of minerals, add the amino acid solution in Step 1 to obtain the first mixed solution;
步骤3:称取对应量的维生素,将所述维生素中脂溶性的维生素加入步骤1中的脂肪乳剂,得到第二混合液;将所述维生素中水溶性的维生素加入步骤1中的葡萄糖溶液,得到第三混合液;Step 3: Weigh the corresponding amount of vitamins, add the fat-soluble vitamins in the vitamins to the fat emulsion in step 1 to obtain a second mixed solution; add the water-soluble vitamins in the vitamins to the glucose solution in step 1, to obtain the third mixed solution;
步骤4:将步骤2中的第一混合液与步骤3中的第二混合液和第三混合液混合,补充注射用水,得到生酮肠外营养液。Step 4: Mix the first mixed solution in step 2 with the second mixed solution and the third mixed solution in step 3, and supplement water for injection to obtain a ketogenic parenteral nutrition solution.
实施例3Example 3
本实施例为2:1型生酮(脂肪类物质重量:葡萄糖和氨基酸重量之和为2:1),3岁以上人群适用,肠外生酮营养液的参数为能量:79.6kcal/100ml,渗透压:554mOsm/L,氨基酸3.3g/100mL,脂肪类物质7.2g/100mL,葡萄糖0.3g/100mL,维生素28.93mg/100mL,矿物质327.33mg/ml,乳化剂1.34g/100mL,醋酸钠4.29mmol/100mL。This example is 2:1 type ketogenic (weight of fatty substances: the sum of the weight of glucose and amino acid is 2:1), suitable for people over 3 years old, and the parameter of parenteral ketogenic nutrient solution is energy: 79.6kcal/100ml, Osmotic pressure: 554mOsm/L, amino acids 3.3g/100mL, fatty substances 7.2g/100mL, glucose 0.3g/100mL, vitamins 28.93mg/100mL, minerals 327.33mg/ml, emulsifier 1.34g/100mL, sodium acetate 4.29 mmol/100mL.
生酮肠外营养液的制备方法:Preparation method of ketogenic parenteral nutrition solution:
步骤1:称取对应量的氨基酸和无水醋酸与注射用水配制成氨基酸溶液,称取对应量的葡萄糖与注射用水配制成葡萄糖溶液,称取对应量的脂肪类物质、乳化剂和氢氧化钠与注射用水配制成脂肪乳剂;Step 1: Weigh corresponding amounts of amino acids and anhydrous acetic acid and water for injection to prepare amino acid solution, take corresponding amounts of glucose and water for injection to prepare glucose solution, weigh corresponding amounts of fatty substances, emulsifier and sodium hydroxide It is formulated into a fat emulsion with water for injection;
步骤2:称取对应量的矿物质,加入步骤1中的氨基酸溶液,得到第一混合液;Step 2: Weigh the corresponding amount of minerals, add the amino acid solution in Step 1 to obtain the first mixed solution;
步骤3:称取对应量的维生素,将所述维生素中脂溶性的维生素加入步骤1中的脂肪乳剂,得到第二混合液;将所述维生素中水溶性的维生素加入步骤1中的葡萄糖溶液,得到第三混合液;Step 3: Weigh the corresponding amount of vitamins, add the fat-soluble vitamins in the vitamins to the fat emulsion in step 1 to obtain a second mixed solution; add the water-soluble vitamins in the vitamins to the glucose solution in step 1, to obtain the third mixed solution;
步骤4:将步骤2中的第一混合液与步骤3中的第二混合液和第三混合液混合,补充注射用水,得到生酮肠外营养液。Step 4: Mix the first mixed solution in step 2 with the second mixed solution and the third mixed solution in step 3, and supplement water for injection to obtain a ketogenic parenteral nutrition solution.
实施例4Example 4
本实施例为2.5:1型生酮(脂肪类物质重量:葡萄糖和氨基酸重量之和为2.5:1),3岁以上人群适用,肠外生酮营养液的参数为能量:68.9kcal/100ml,渗透压:477mOsm/L,氨基酸1.9g/100mL,脂肪类物质6.5g/100mL,葡萄糖0.7g/100mL,维生素28.93mg/100mL,矿物质327.33mg/ml,乳化剂1.34g/100mL,醋酸钠2.47mmol/100mL。This example is 2.5:1 type ketogenic (the weight of fatty substances: the sum of the weight of glucose and amino acid is 2.5:1), suitable for people over 3 years old, and the parameters of the parenteral ketogenic nutrient solution are energy: 68.9kcal/100ml, Osmotic pressure: 477mOsm/L, amino acids 1.9g/100mL, fatty substances 6.5g/100mL, glucose 0.7g/100mL, vitamins 28.93mg/100mL, minerals 327.33mg/ml, emulsifier 1.34g/100mL, sodium acetate 2.47 mmol/100mL.
生酮肠外营养液的制备方法:The preparation method of ketogenic parenteral nutrition solution:
步骤1:step 1:
步骤1:称取对应量的氨基酸和无水醋酸与注射用水配制成氨基酸溶液,称取对应量的葡萄糖与注射用水配制成葡萄糖溶液,称取对应量的脂肪类物质、乳化剂和氢氧化钠与注射用水配制成脂肪乳剂;Step 1: Weigh corresponding amounts of amino acids and anhydrous acetic acid and water for injection to prepare amino acid solution, take corresponding amounts of glucose and water for injection to prepare glucose solution, weigh corresponding amounts of fatty substances, emulsifier and sodium hydroxide It is formulated into a fat emulsion with water for injection;
步骤2:称取对应量的矿物质,加入步骤1中的氨基酸溶液,得到第一混合液;Step 2: Weigh the corresponding amount of minerals, add the amino acid solution in Step 1 to obtain the first mixed solution;
步骤3:称取对应量的维生素,将所述维生素中脂溶性的维生素加入步骤1中的脂肪乳剂,得到第二混合液;将所述维生素中水溶性的维生素加入步骤1中的葡萄糖溶液,得到第三混合液;Step 3: Weigh the corresponding amount of vitamins, add the fat-soluble vitamins in the vitamins to the fat emulsion in step 1 to obtain a second mixed solution; add the water-soluble vitamins in the vitamins to the glucose solution in step 1, to obtain the third mixed solution;
步骤4:将步骤2中的第一混合液与步骤3中的第二混合液和第三混合液混合,补充注射用水,得到生酮肠外营养液。Step 4: Mix the first mixed solution in step 2 with the second mixed solution and the third mixed solution in step 3, and supplement water for injection to obtain a ketogenic parenteral nutrition solution.
实施例5Example 5
本实施例为3.5:1型生酮(脂肪类物质重量:葡萄糖和氨基酸重量之和为3.5:1),3岁以上人群适用,肠外生酮营养液的参数为能量:68.9kcal/100ml,渗透压:436mOsm/L,氨基酸1.84g/100mL,脂肪类物质7.91g/100mL,葡萄糖0.42g/100mL,维生素28.93mg/100mL,矿物质327.33mg/ml,乳化剂1.48g/100mL,醋酸钠2.39mmol/100mL。This example is 3.5:1 type ketogenic (the weight of fatty substances: the sum of the weight of glucose and amino acids is 3.5:1), suitable for people over 3 years old, and the parameters of the parenteral ketogenic nutrient solution are energy: 68.9kcal/100ml, Osmotic pressure: 436mOsm/L, amino acids 1.84g/100mL, fatty substances 7.91g/100mL, glucose 0.42g/100mL, vitamins 28.93mg/100mL, minerals 327.33mg/ml, emulsifier 1.48g/100mL, sodium acetate 2.39 mmol/100mL.
生酮肠外营养液的制备方法:Preparation method of ketogenic parenteral nutrition solution:
步骤1:称取对应量的氨基酸和无水醋酸与注射用水配制成氨基酸溶液,称取对应量的葡萄糖与注射用水配制成葡萄糖溶液,称取对应量的脂肪类物质、乳化剂和氢氧化钠与注射用水配制成脂肪乳剂;Step 1: Weigh corresponding amounts of amino acids and anhydrous acetic acid and water for injection to prepare amino acid solution, take corresponding amounts of glucose and water for injection to prepare glucose solution, weigh corresponding amounts of fatty substances, emulsifier and sodium hydroxide It is formulated into a fat emulsion with water for injection;
步骤2:称取对应量的矿物质,加入步骤1中的氨基酸溶液,得到第一混合液;Step 2: Weigh the corresponding amount of minerals, add the amino acid solution in Step 1 to obtain the first mixed solution;
步骤3:称取对应量的维生素,将所述维生素中脂溶性的维生素加入步骤1中的脂肪乳剂,得到第二混合液;将所述维生素中水溶性的维生素加入步骤1中的葡萄糖溶液,得到第三混合液;Step 3: Weigh the corresponding amount of vitamins, add the fat-soluble vitamins in the vitamins to the fat emulsion in step 1 to obtain a second mixed solution; add the water-soluble vitamins in the vitamins to the glucose solution in step 1, to obtain the third mixed solution;
步骤4:将步骤2中的第一混合液与步骤3中的第二混合液和第三混合液混合,补充注射用水,得到生酮肠外营养液。Step 4: Mix the first mixed solution in step 2 with the second mixed solution and the third mixed solution in step 3, and supplement water for injection to obtain a ketogenic parenteral nutrition solution.
需要说明的是上述氨基酸溶液、葡萄糖溶液和脂肪乳剂均可通过商业购买,购买后直接根据所需用量直接用于配制;或者商业定制:向生产厂家定制特定浓度的溶液,厂家通过现有技术得到对应浓度的氨基酸溶液、葡萄糖溶液和脂肪乳剂。It should be noted that the above-mentioned amino acid solution, glucose solution and fat emulsion can be purchased commercially, and can be directly used for preparation according to the required amount after purchase; or commercial customization: a solution of a specific concentration is customized to the manufacturer, and the manufacturer obtains it through the existing technology. Corresponding concentrations of amino acid solution, glucose solution and fat emulsion.
现有技术可通过将氨基酸配制成氨基酸溶液的过程包括称取对应量的氨基酸、无水醋酸和注射用水通过搅拌、过滤、冷冻、干燥等步骤配制成氨基酸溶液;将葡萄糖配制成葡萄糖溶液的过程包括称取对应量的葡萄糖,加入注射用水,搅拌,配制成葡萄糖溶液;称取对应量的脂肪类物质、乳化剂制备油相和水相,然后搅拌混合,加入氢氧化钠、加注射用水、均质等步骤配制成脂肪乳剂。In the prior art, the process of preparing amino acids into amino acid solutions includes weighing corresponding amounts of amino acids, anhydrous acetic acid and water for injection to prepare amino acid solutions through steps such as stirring, filtration, freezing, and drying; the process of preparing glucose into glucose solutions. Including weighing the corresponding amount of glucose, adding water for injection, stirring to prepare a glucose solution; weighing the corresponding amount of fatty substances and emulsifiers to prepare oil phase and water phase, then stirring and mixing, adding sodium hydroxide, adding water for injection, Steps such as homogenization are formulated into a fat emulsion.
上述生酮肠外营养液的制备方法中,步骤3中将所述维生素中脂溶性的维生素加入步骤1中的脂肪乳剂,得到第二混合液;将所述维生素中水溶性的维生素加入步骤1中的葡萄糖溶液,得到第三混合液。如果权利要求1中维生素只有脂溶性维生素,则步骤3只包括将所述维生素中脂溶性的维生素加入步骤1中的脂肪乳剂,得到第二混合液,之后将第一混合液、第二混合液和葡萄糖溶液混合,(如需补水则补水),得到生酮肠外营养液。如果权利要求1中维生素只有水溶性维生素,则步骤3只包括将所述维生素中水溶性的维生素加入步骤1中的葡萄糖溶液,得到第三混合液,之后将第一混合液、脂肪乳剂和第三混合液混合,(如需补水则补水),得到生酮肠外营养液。In the preparation method of the above-mentioned ketogenic parenteral nutrition solution, in step 3, the fat-soluble vitamins in the vitamins are added to the fat emulsion in step 1 to obtain a second mixed solution; the water-soluble vitamins in the vitamins are added in step 1 in the glucose solution to obtain the third mixed solution. If the vitamins in claim 1 are only fat-soluble vitamins, then step 3 only includes adding the fat-soluble vitamins in the vitamins to the fat emulsion in step 1 to obtain a second mixed solution, and then adding the first mixed solution and the second mixed solution. It is mixed with glucose solution (replenish water if necessary) to obtain ketogenic parenteral nutrition solution. If the vitamins in claim 1 are only water-soluble vitamins, then step 3 only includes adding the water-soluble vitamins in the vitamins to the glucose solution in step 1 to obtain a third mixed solution, and then adding the first mixed solution, the fat emulsion and the first mixed solution. The three mixed solutions are mixed, (replenish water if necessary) to obtain a ketogenic parenteral nutrition solution.
对应量的无水醋酸和对应量的氢氧化钠指的是和所需营养液中醋酸钠具有相同摩尔数的醋酸和氢氧化钠;步骤4中第一混合液和第二混合液的混合,使得醋酸和氢氧化钠反应生成营养液中的醋酸钠。The anhydrous acetic acid of the corresponding amount and the sodium hydroxide of the corresponding amount refer to the acetic acid and the sodium hydroxide having the same mole number as the sodium acetate in the required nutrient solution; the mixing of the first mixed solution and the second mixed solution in step 4, The acetic acid and sodium hydroxide are reacted to form sodium acetate in the nutrient solution.
所述氨基酸溶液的氨基酸优选配制质量浓度为6%或10%,所述葡萄糖溶液的优选配制质量浓度为10%,所述脂肪乳剂中油类物质的优选配制质量浓度为20%。当氨基酸为19种时,氨基酸溶液的优选配制质量浓度为6%;当氨基酸为18种时,氨基酸溶液的优选配制质量浓度为10%。The amino acid of the amino acid solution is preferably formulated at a mass concentration of 6% or 10%, the glucose solution is preferably formulated at a mass concentration of 10%, and the oil in the fat emulsion is preferably formulated at a mass concentration of 20%. When there are 19 kinds of amino acids, the preferred preparation mass concentration of the amino acid solution is 6%; when there are 18 kinds of amino acids, the preferred preparation mass concentration of the amino acid solution is 10%.
本发明中根据各物质所需重量来称量,称量选用不同精度的称量仪器,所产生的误差不影响本发明中各物质在所配制营养液中作用的发挥。称量需要精确到十分位的物质选用精确到0.1g的电子天平,称量需要精确到百分位的物质选用精确到0.01g的电子天平,称量需要精确到千分位的物质选用精确到0.001g的电子天平。In the present invention, each substance is weighed according to the required weight, and weighing instruments with different precisions are used for weighing. For substances that need to be weighed to the tenth place, choose an electronic balance that is accurate to 0.1g. For substances that need to be weighed to the percentile, choose an electronic balance that is accurate to 0.01g. 0.001g electronic balance.
本发明制定了使用的时间、速度和监测指标:要求本发明营养液连续使用时间不超过2周;根据脂肪的量来确定输注时间,一定脂肪量的输注时间(小时)不短于所需输注脂肪类物质的重量/0.15/人体体重(其中脂肪类物质的质量以g计,人体重量以kg计)。每周需要复查肝肾功、电解质、血脂、血糖、血酮水平等,决定是否继续使用。The present invention formulates the time, speed and monitoring index of use: the continuous use time of the nutrient solution of the present invention is required not to exceed 2 weeks; the infusion time is determined according to the amount of fat, and the infusion time (hour) of a certain amount of fat is not shorter than the specified amount of fat. The weight of fatty substances to be infused/0.15/body weight (wherein the mass of fatty substances is in g, and the body weight is in kg). It is necessary to review liver and kidney function, electrolytes, blood lipids, blood sugar, blood ketone levels, etc. every week to decide whether to continue use.
本发明制定了使用的适应症和禁忌症。适应症:难治性癫痫、葡萄糖载体缺乏症、丙酮酸脱氢酶缺乏症等。禁忌症:所有脂肪利用障碍相关疾病、氨基酸代谢疾病急性期、严重肝肾功能损害等、慢性代谢性酸中毒、高脂血症、高血压或经临床医师评估后不能使用的疾病等。The present invention establishes the indications and contraindications for use. Indications: refractory epilepsy, glucose carrier deficiency, pyruvate dehydrogenase deficiency, etc. Contraindications: all diseases related to fat utilization disorders, acute phase of amino acid metabolism diseases, severe liver and kidney function damage, etc., chronic metabolic acidosis, hyperlipidemia, hypertension or diseases that cannot be used after evaluation by clinicians, etc.
所述脂肪类物质的重量与所述葡萄糖和所述氨基酸重量之和的比例为2:1~4:1时候生酮效果较好。When the ratio of the weight of the fatty substance to the sum of the weight of the glucose and the amino acid is 2:1 to 4:1, the ketogenic effect is better.
在临床上,4:1型、3:1型和2:1型生酮应用最为广泛,可根据病人情况从中进行选择,也可根据病人情况选用其他生酮比例。In clinical practice, 4:1 type, 3:1 type and 2:1 type of ketosis are the most widely used, which can be selected according to the patient's situation, or other ketogenic ratios can be selected according to the patient's situation.
效果说明Effect description
患者应用实例1Patient Application Example 1
患儿张某某,男,11月,婴儿痉挛症(8月开始生酮奶治疗发作),因“腹痛、腹胀、呕吐1天”收治入院;入院后腹部平片显示肠管积气明显且有液平;医生考虑主要诊断为1.完全性肠梗阻2.婴儿痉挛症;经治疗后病情平稳,需要短期肠外营养支持。此时,营养科医生介入制定营养方案:患儿体重8kg,目前肠外营养液空间为330ml。患儿平素使用4:1生酮奶进行治疗,故选用上述4:1型生酮肠外营养配方(3岁以下型)共330ml开始肠外营养输注,保证营养摄入,输注速度15ml/h,供需输注22小时。输注持续共5天,每天监测血酮血糖,血酮保持2.5mmol/L-4.5mmol/L,血糖3.5-4.8mol/L,期间无痉挛发作频率增加。经治疗5天后,肠梗阻逐渐缓解,开始增加生酮奶,减少生酮肠外营养液,2周后顺利出院,继续生酮奶喂养,临床营养门诊随访。The child Zhang Moumou, male, in November, suffered from infantile spasms (the onset of ketogenic milk treatment started in August), and was admitted to the hospital because of "abdominal pain, abdominal distension, and vomiting for 1 day". Fluid level; the doctor considered the main diagnosis as 1. Complete intestinal obstruction 2. Infantile spasms; after treatment, the condition was stable and short-term parenteral nutrition support was needed. At this time, the nutritionist intervened to formulate a nutritional plan: the child weighed 8kg, and the current space for parenteral nutrition was 330ml. Children usually use 4:1 ketogenic milk for treatment, so the above 4:1 ketogenic parenteral nutrition formula (under 3 years old) is used to start parenteral nutrition infusion with a total of 330ml to ensure nutritional intake, and the infusion rate is 15ml /h, supply and demand infusion for 22 hours. The infusion continued for a total of 5 days, and the blood ketones and blood glucose were monitored every day. After 5 days of treatment, the intestinal obstruction was gradually relieved, and the ketogenic milk was increased and the ketogenic parenteral nutrition solution was reduced. After 2 weeks, the patient was discharged from the hospital and continued to be fed with ketogenic milk. The clinical nutrition clinic was followed up.
患者应用实例2Patient application example 2
患儿王某某,女,4岁2,难治性癫痫(3岁开始生酮饮食治疗),因“上腹部胀痛10小时,伴有恶心及呕吐”收治入院;入院检查血淀粉酶1066U/L,脂肪酶4213U/L.血常规示:WBC15.77×109/L,N0.733.上腹部CT结果示急性胰腺炎。主要诊断为1.急性胰腺炎2.难治性癫痫;经治疗生命体征平稳后,需要短期肠外营养支持,请营养科会诊:患儿体重15kg,目前肠外营养液空间为520ml。患儿平常已使用2:1自制配餐进行三餐,自测血酮2.7~4.5mmol/L,血糖3.6~5.2mmol/L,病情控制稳定。重症胰腺炎虽然也可以采用鼻空肠管泵入高糖低脂短肽肠内配方进行空肠营养喂养,但患儿为长期生酮饮食治疗的难治性癫痫患者,冒然使用此方法可能导致癫痫发作。故短期仍然继续禁食,并选用上述2:1型生酮肠外营养配方(3岁以上型)开始肠外营养输注(液体520ml),输注速度38ml/h,供需输注13.6小时。持续输注时间共13天,每天监测血酮血糖,血酮保持2.2mmol/L~3.8mol/L,血糖3.3~4.3mol/L,期间癫痫发作频率无增加。第一周结束转氨酶、胆红素、血甘油三酯水平较入院时无明显升高。出院前,营养医师再次会诊:考虑患儿现癫痫发作频率低,病情控制稳定,但长期生酮饮食为可能为胰腺炎的诱发因素之一,建议逐渐下调生酮饮食比例,逐渐恢复普通饮食。The child Wang Moumou, female, 4 years old, 2, with refractory epilepsy (started ketogenic diet treatment at the age of 3), was admitted to the hospital because of "upper abdominal pain for 10 hours, accompanied by nausea and vomiting"; blood amylase was checked at 1066U. /L, lipase 4213U/L. Blood routine showed: WBC15.77×109/L, N0.733. Upper abdominal CT results showed acute pancreatitis. The main diagnosis is 1. acute pancreatitis 2. refractory epilepsy; after the vital signs are stable after treatment, short-term parenteral nutrition support is needed, please consult the nutrition department: the child weighs 15kg, and the current parenteral nutrition solution space is 520ml. The child has usually used a 2:1 homemade meal for three meals, self-measured blood ketones 2.7-4.5 mmol/L, blood sugar 3.6-5.2 mmol/L, and the condition is under stable control. Although severe pancreatitis can also be fed with high-sugar and low-fat short peptide enteral formula by nasojejunal tube, the child is a patient with refractory epilepsy treated with long-term ketogenic diet, and this method may lead to epilepsy. attack. Therefore, fasting was continued in the short term, and the above-mentioned 2:1 ketogenic parenteral nutrition formula (over 3 years old) was used to start parenteral nutrition infusion (liquid 520ml), the infusion rate was 38ml/h, and the supply and demand infusion was 13.6 hours. The continuous infusion time was 13 days, and the blood ketone and blood sugar were monitored every day. At the end of the first week, the levels of transaminase, bilirubin and blood triglyceride were not significantly higher than those at the time of admission. Before discharge, the nutritionist should consult again: Considering that the child has low seizure frequency and stable disease control, but long-term ketogenic diet may be one of the predisposing factors for pancreatitis, it is recommended to gradually reduce the proportion of ketogenic diet and gradually restore normal diet.
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the protection of the present invention. within the range.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910213658.3A CN109939135A (en) | 2019-03-20 | 2019-03-20 | A kind of ketogenic parenteral nutrition solution and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910213658.3A CN109939135A (en) | 2019-03-20 | 2019-03-20 | A kind of ketogenic parenteral nutrition solution and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109939135A true CN109939135A (en) | 2019-06-28 |
Family
ID=67010317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910213658.3A Pending CN109939135A (en) | 2019-03-20 | 2019-03-20 | A kind of ketogenic parenteral nutrition solution and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109939135A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111657497A (en) * | 2020-06-28 | 2020-09-15 | 深圳市捷利康生物科技有限公司 | Ketogenic diet for resisting food protein allergy and preparation method thereof |
CN112656933A (en) * | 2021-01-08 | 2021-04-16 | 天津市第三中心医院 | Parenteral nutrient solution suitable for pneumonia patients |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1640396A (en) * | 2004-01-02 | 2005-07-20 | 广东奇方药业有限公司 | Novel medicinal compositions |
CN106265857A (en) * | 2015-05-19 | 2017-01-04 | 四川科伦药业股份有限公司 | The preparation method of the fat milk of packed with three-cavity bag, aminoacid and glucose injection |
-
2019
- 2019-03-20 CN CN201910213658.3A patent/CN109939135A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1640396A (en) * | 2004-01-02 | 2005-07-20 | 广东奇方药业有限公司 | Novel medicinal compositions |
CN106265857A (en) * | 2015-05-19 | 2017-01-04 | 四川科伦药业股份有限公司 | The preparation method of the fat milk of packed with three-cavity bag, aminoacid and glucose injection |
Non-Patent Citations (5)
Title |
---|
DE JUNG: "Safety and role of ketogenic parenteral nutrition for intractable childhood epilepsy", 《BRAIN & DEVELOPMENT》 * |
史斌等: "《临床容量治疗学》", 31 December 2008, 天津科学技术出版社 * |
广东省药学会: "肠外营养临床药学共识( 第二版)", 《今日药学》 * |
营养学组: "《中国生理科学会学术会议论文摘要汇编 营养》", 31 August 1964 * |
蔡华等: "《现代产科护理精要》", 30 September 2018, 天津科学技术出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111657497A (en) * | 2020-06-28 | 2020-09-15 | 深圳市捷利康生物科技有限公司 | Ketogenic diet for resisting food protein allergy and preparation method thereof |
CN112656933A (en) * | 2021-01-08 | 2021-04-16 | 天津市第三中心医院 | Parenteral nutrient solution suitable for pneumonia patients |
CN112656933B (en) * | 2021-01-08 | 2023-08-08 | 天津市第三中心医院 | A parenteral nutrition solution suitable for patients with pneumonia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4009265A (en) | Methods and formulations for the treatment of obesity | |
RU2420209C2 (en) | Long-term alimentation for cancer patient | |
KR101075816B1 (en) | Total enteral nutritious composition | |
Pereira | Nutritional care of the extremely premature infant | |
JPH08231411A (en) | Method for feeding nutrition to aged patient | |
EP0630181A4 (en) | Nutritional product for trauma and surgery patients. | |
US20120277170A1 (en) | Nutritive compositions and methods of using same | |
Ahmed et al. | Protein-energy malnutrition in children | |
CN109090580A (en) | A kind of specific full nutritional formulas and preparation method thereof for tumor patient | |
Jain et al. | Parenteral nutrition | |
CN105558046A (en) | Formula food with special medicinal purpose and suitable for liver disease and preparation method thereof | |
CN109939135A (en) | A kind of ketogenic parenteral nutrition solution and preparation method thereof | |
Littlewood et al. | Rationale of modern dietary recommendations in cystic fibrosis | |
JP3137273B2 (en) | Compositions effective for diabetes | |
Rohr et al. | Reinstitution of pegvaliase therapy during lactation | |
CN105638900A (en) | Special medical food for patients in emergency states and preparation method thereof | |
Rose et al. | Nutrient needs of the preterm infant | |
Druml | The renal failure patient | |
CN113519850A (en) | Tumor total nutrient emulsion, preparation method and application thereof | |
Mehler et al. | Treatment of anorexia nervosa with total parenteral nutrition | |
Tok et al. | Vitamin D and Effective Mechanisms in the Control of Body Weight | |
Price | Parenteral nutrition | |
Yuen et al. | Treatment of Iatrogenic Essential Fatty Acid Deficiency with a Lipid-Rich Matrix in a Child with Intestinal Failure-Associated Liver Disease: Case Report | |
Acosta | Evaluation of nutrition status | |
Starker et al. | Parenteral nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190628 |
|
RJ01 | Rejection of invention patent application after publication |